CAR T-cell Therapy

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.


Latest News

Five Under 5: Top Oncology Videos for the Week of 2/9
Five Under 5: Top Oncology Videos for the Week of 2/9

February 16th 2025

The top 5 videos of the week cover insights in plexiform neurofibromas, melanoma, myeloma, leukemia, and LBCL.

Multiple Myeloma | Image Credit: ©  LASZLO– stock.adobe.com
Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma

February 15th 2025

FDA
FDA Awards RMAT Designation to NXC-201 for Relapsed/Refractory AL Amyloidosis

February 13th 2025

FDA hematology approvals
Hematologic Oncology Field Sees Almost 20 FDA Approvals in 2024

February 11th 2025

Marginal Zone Lymphoma | Image Credit: © LASZLO – stock.adobe.com
Liso-Cel Generates Responses in R/R Marginal Zone Lymphoma

February 10th 2025

More News